Here's Why Astrazeneca (AZN) is a Strong Growth Stock

Zacks highlights AstraZeneca (AZN) as a notable growth stock, assigning it a #3 (Hold) Zacks Rank but strong 'A' VGM and 'B' Growth Style Scores. The biopharmaceutical firm projects 9.3% year-over-year earnings growth for the current fiscal year, supported by recent analyst upgrades contributing to a $4.49 per share FY2025 consensus estimate and a 4.2% average earnings surprise. This blend of robust style scores and positive growth indicators positions AZN as a potential consideration for growth-focused investors.

Analysis

AstraZeneca (AZN) presents a bifurcated profile based on Zacks' proprietary metrics, combining a neutral rank with strong underlying growth indicators. The company is assigned a Zacks Rank #3 (Hold), which typically denotes stable but not significantly rising earnings estimates. However, this is contrasted by a top-tier 'A' grade for its composite VGM (Value, Growth, Momentum) Score and a strong 'B' for its Growth Style Score. Underscoring the growth case is a forecast for 9.3% year-over-year earnings growth in the current fiscal year and a consistent history of beating expectations, reflected by an average earnings surprise of 4.2%. Looking ahead to fiscal 2025, while two analysts have revised earnings estimates upward in the past 60 days, the Zacks Consensus Estimate has remained unchanged at $4.49 per share, suggesting these positive revisions have not yet been sufficient to shift the broader analyst consensus.

Key Decisions for Investors

• Investors with a growth mandate should consider AstraZeneca's projected 9.3% earnings growth and history of positive earnings surprises, which suggest potential upside despite its neutral 'Hold' rating.
• Monitor future analyst estimate revisions closely, as a shift in the $4.49 consensus estimate for fiscal 2025 would be a significant catalyst, validating the positive view of the few analysts who have recently upgraded their forecasts.
• The stock's top 'A' rating for the composite VGM score indicates it may appeal to investors seeking a balanced profile, suggesting potential resilience even if pure growth factors do not accelerate as projected.